Herein, we propose a novel inhibitory pathway of NF-κB-mediated PLCγ2-PKC activation by auraptene in human platelets, and further supported that auraptene possesses potent activity for clinical therapeutic or prophylactic application for treatment with thromboembolic diseases. This evidence concerns the gene PLCG2 and Thromboembolism.